Alcon Inc. Ordinary Shares ALC

The Motley Fool 11 nov

Alcon reported Q3 2026 earnings with ~6% full-year net sales growth guidance and double-digit core EPS growth. The company is defending its premium intraocular lens market share against competitors through new products (Vivity Pro, TruPlus), expanding UNITY surgical equipment placements to 40% of U.S. teaching hospitals, and acquiring Neurotech Pharmaceuticals for retinal disease treatment with peak sales potential of $250-400 million. Management emphasized outpacing the 3% baseline eye care market growth through operational efficiency and margin expansion.

Zacks Investment Research 11 nov

Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.

Zacks Investment Research 10 nov

Alcon reported $2.72 billion in revenue for Q3 2026, up 4.9% year-over-year, slightly missing the consensus estimate of $2.73 billion. EPS of $0.91 exceeded expectations of $0.89. The company showed strong growth in Vision Care (+5.8%) and Equipment/other segments (+10.7%), but faced headwinds in Implantables (-2.3%) and Other revenues (-20%). The stock has outperformed the broader market with a +16.8% return over the past month.

Zacks Investment Research 5 nov

Alcon (ALC) shares surged 6.8% to $77.31 on investor optimism ahead of its third quarter 2026 earnings release on November 11. The company is expected to report EPS of $0.89 (up 12.7% YoY) and revenues of $2.73 billion (up 5.6% YoY). However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to maintain momentum without further positive estimate revisions. NeuroPace (NPCE), a peer in the medical instruments industry, also gained 8.4% but remains down 2.8% over the past month.

The Motley Fool 13 ago

Bill Ackman's Pershing Square deployed 85% of its $5 billion capital raise by purchasing Netflix, Visa, Mastercard, S&P Global, Intercontinental Exchange, and Alcon. The fund targeted stocks that have sold off due to AI disruption concerns, believing these companies have competitive advantages that will allow them to thrive despite AI-related headwinds.